Archive for the ‘Uncategorized’ Category

Oral argument by telephone

Sunday, March 22nd, 2020

Many of the April oral arguments at the Federal Circuit are scheduled to be conducted by telephone. The court has rarely conducted oral arguments by telephone in the past. If you would like to listen to an example of an oral argument at the Federal Circuit that was conducted by telephone, see this previous post from 2013: [Link].

Jurisdictional statements

Friday, March 13th, 2020

The first step in any precedential opinion issued by the Federal Circuit is an explanation of why it has jurisdiction. The court clearly takes that step seriously and a party cannot even waive the jurisdictional issue. It occurred to me in reading yesterday’s short per curiam disposition that the jurisdictional statement was not present. And, the basis for the court finding that it has jurisdiction is certainly not explained in Rule 36 judgments. Like all things with respect to Rule 36 judgments, we have to assume the court got it right . . . because it didn’t say so.

Quote for the day

Wednesday, March 4th, 2020

“The patent law is designed to serve the small inventor as well as the giant research organization.”

Arkie Lures, Inc. v. Gene Larew Tackle, Inc., 119 F.3d 953 (Fed. Cir. 1997)(Judge Newman, author).

1000

Friday, February 28th, 2020

717Madisonplace.com celebrated a milestone yesterday by reaching one thousand posts.

Thank you for reading and listening!

En banc review requested in Polaris v. Kingston, on Arthrex issues

Thursday, February 27th, 2020

Both the United States and Polaris have requested en banc review in the recent Federal Circuit decision of Polaris v. Kingston. This case presents substantially similar issues as those that were presented in Arthrex. Namely, should PTAB judges be considered principal officers of the United States, who must be nominated by the “President” and confirmed by the Senate? My understanding is that Polaris actually raised this issue in its appeal briefing before the parties in Arthrex did so; but, due to the timing of oral arguments, the Federal Circuit panel in Arthrex was able to rule first (in a very speedy opinion after oral argument). During its oral argument, Polaris argued that its case would be a better vehicle for en banc review than the Arthrex case. I tend to agree; although, I personally would like to see both cases considered together in a joint en banc review.

You can read Solicitor Krause’s en banc petition for the PTO here:

You can read Polaris’ en banc petition here:

Video of oral argument in FTC v. Qualcomm

Saturday, February 22nd, 2020

I seem to remember that someone once commented that the Federal Circuit courtrooms could easily implement video recordings of their oral arguments — if the court chose to do so. The Ninth Circuit has been doing so for many years. Do you think the Federal Circuit should add video recordings?

Here is the video of the recent oral argument at the Ninth Circuit in FTC v. Qualcomm:

Oral argument of the month: In re Google

Thursday, February 13th, 2020

The oral argument of the month is from the order today in In re Google, 2019-126 (Fed. Cir. February 13, 2020). [Link]. The subject matter concerns the rather dry subject of venue; but, the oral argument is very interesting. Moreover, it highlights how the courts are being forced to think carefully about how laws written in the 19th and 20th centuries should be applied in the information age.

A careful listener will hear a reference to The Scarlet Pimpernel by Judge Wallach.

Who is left from the In re Alappat panel?

Friday, January 31st, 2020

Back on Friday, July 29, 1994, the CAFC decided In re Alappat, 33 F.3d 1526 (Fed. Cir. 1994). (A memorable date for me, as I was taking the Colorado bar exam on that date.) The opinion was a highly fractured one with multiple dissents. One of the main issues of contention was whether the Federal Circuit had jurisdiction to hear the appeal, because it stemmed from an enlarged panel decision at the Board. Whether the USPTO had the authority to use such enlarged panels under the statute in place back then had to be determined to decide if the appellate court had jurisdiction.

Judges RICH, NEWMAN, LOURIE and RADER, voted in favor of the court having jurisdiction.

Judges ARCHER, Chief Judge, NIES and PLAGER, concurred in the conclusion.

Judges MAYER, MICHEL, CLEVENGER and SCHALL dissented.

This issue seems relevant to me because Alappat was mentioned again today in the concurrence in Polaris v. Kingston.

The Arthrex panel’s underestimation of the Director’s power is particularly evident in light of this court’s prior en banc decision in In re Alappat, 33 F.3d 1526 (Fed. Cir. 1994), abrogated on other grounds by In re Bilski, 545 F.3d 943 (Fed. Cir. 2008). Alappat contained strong language about the ability to control the composition and size of panels. See, e.g.id. at 1535 (noting that “the Board is merely the highest level of the Examining Corps, and like all other members of the Examining Corps, the Board operates subject to the Commissioner’s overall ultimate authority and responsibility”). While the duties of the Board and the Director have changed since Alappat was decided, the authority to determine the Board’s composition for reconsideration of an examiner’s patentability determination mirrors the current authority with respect to inter partes review. Compare 35 U.S.C. § 6(c) (2012) (giving the Director authority to designate “at least 3 members of the Patent Trial and Appeal Board” to review “[e]ach appeal, derivation proceeding, post-grant review, and inter partes review”), with 35 U.S.C. §7(b) (1988) (giving the Commissioner power to designate “at least three members of the Board of Appeals and Interferences” to review “adverse decisions of examiners upon applications for patents”). Therefore, I believe the panel should have at least discussed how Alappat’s view of the power to control the Board might impact the Appointments Clause analysis.

Polaris v. Kingston, slip opinion at footnote 5 (Fed. Cir. January 31, 2020)(Judges Hughes and Wallach in concurrence).

One should keep in mind that the Alappat decision was highly fractured. Three of the majority remain on the court, as do three of the dissenters. However, an en banc panel from an appeal of either Arthrex or Polaris would only include full time circuit judges — not senior judges. Therefore, Judges Newman and Lourie would be the only surviving members from Alappat to serve on such an en banc panel.

This prior post provides some historical context for Alappat, as well: [In 1992, 75% of the BPAI judges objected to the manipulation of the composition of Board panels].

Since Judge Hughes compared the current statute to a previous statute with respect to the Board, I wonder if there is any merit in going back further in time to when the Supreme Court decided Brenner v. Manson? See this earlier post for more on that, including Supreme Court audio: [Brenner v. Manson — footnote 6.].

Oral argument of the week: Telesign v. Twilio

Monday, January 27th, 2020

The oral argument of the week is from TELESIGN CORPORATION v. TWILIO, INC., No. 2019-1312 (Fed. Cir. Jan. 9, 2020).

I thought this oral argument might interest those of you who like to follow patent eligibility issues.

The panel of Judges Dyk, Taranto, and Chen issued a Rule 36 Judgment [Link].

The oral argument is available here:

Denver Patent Office to host biotech roundtable

Saturday, January 25th, 2020

If you are in Denver on Thursday, January 30th, the Denver Patent Office is hosting a biotech roundtable:

Details:

Thursday, January 30, 2020

1:30 p.m. – 4:00 p.m.

Registration & Networking begins at 1:00 p.m.

United States Patent and Trademark Offices

1961 Stout St

15th Floor Conference Room

Denver, CO 80294

1:00 p.m. – 1:30 p.m. Registration and Networking

1:30 p.m. – 1:40 p.m. Introductions

•     Molly Kolcialski, Director of the Rocky Mountain Regional Office of the USPTO

•     Jerry Lorengo, Director of TC3700 (medical, surgical, and diagnostic instruments)

•     Andrew Wang, Director of TC1610 (organic compounds: bio-affecting, body treating, drug delivery, steroids, herbicides, pesticides, cosmetics, and drugs)

1:40 p.m. – 2:10 p.m. Restriction Practice, Renee Claytor, SPE 1651 (Fermentation, Microbiology, Isolated and Recombinant Proteins/Enzymes)

2:10 p.m. – 2:30 p.m. Application Initiatives/Online resources, Ram Shukla, Acting Assistant Regional Director of the Rocky Mountain Regional Office of the USPTO

2:30 p.m. – 2:45 p.m. After-final practice, Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration

2:45 p.m. – 3:00 p.m. Break

3:00 p.m. – 4:00 p.m. Question and Answer Session, Roundtable Discussion to include discussions on 101, written description, and enablement

Registration Link.